Cumulus Oncology Signed a Research Collaboration Agreement with leadXpro to Develop Small Molecules Against Novel Cancer-Focused GPCR Targets
Shots:
- The companies collaborated to discover and develop small molecules targeting an undisclosed and novel cancer-focused GPCR. The collaboration will combine both companies’ expertise to create an initial high-value, lead program
- leadXpro will be responsible to generate novel compounds using its structural biology expertise, combining technology in protein structure determination, coupled with biophysical characterization and computational modelling
- Cumulus Oncology will establish a GPCR portfolio company focusing on novel GPCR targets in tumors & tumor microenvironments. This company will get an option to license the lead compound series as well as the resulting intellectual property from the research collaboration
Ref: Globenewswire | Image: Cumulus Neuroscience
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
